谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Phase I Dose Escalation Trial of the First-in-class TNFR2 Agonist Monoclonal Antibody, HFB200301, in Monotherapy and in Combination with Tislelizumab, an Anti-Pd-1 Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors.

Desamparados Roda,Jon Zugazagoitia,Elena Garralda,Alexander I. Spira,Anthony B. El-Khoueiry,Hani M. Babiker,Peter John Oppelt, Xi Lin,Shaozhen Xie, Margaret E. Chen,Jinping Gan,Gabrielle Wong, Jack Russella Pollard,William Hedrich, John Pallante,Christos Hatzis, Robert H. Andtbacka

Journal of Clinical Oncology（2024）

引用 0|浏览4
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要